Wolverine Trading
FULC icon

Wolverine Trading’s Fulcrum Therapeutics FULC Stock Holding History

Wolverine Trading’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,400
Closed -$116K – 5793
2025
Q2 		$116K Buy
+16,400
New +$87.7K ﹤0.01% 4124
2025
Q1 		– Sell
-41,300
Closed -$193K – 5113
2024
Q4 		$193K Sell
41,300
-10,800
-21% -$39.8K ﹤0.01% 4543
2024
Q3 		$196K Buy
52,100
+14,100
+37% +$105K ﹤0.01% 4111
2024
Q2 		$236K Buy
38,000
+2,500
+7% +$18.9K ﹤0.01% 3667
2024
Q1 		$335K Buy
35,500
+13,800
+64% +$123K ﹤0.01% 3239
2023
Q4 		$146K Buy
21,700
+6,100
+39% +$27.1K ﹤0.01% 3997
2023
Q3 		$69.3K Buy
15,600
+700
+5% +$3.06K ﹤0.01% 4102
2023
Q2 		$47.7K Sell
14,900
-2,700
-15% -$7.93K ﹤0.01% 3963
2023
Q1 		$50K Buy
+17,600
New +$158K ﹤0.01% 3834
2022
Q3 		– Sell
-11,600
Closed -$57K – 4835
2022
Q2 		$57K Buy
+11,600
New +$113K ﹤0.01% 4033

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wolverine Trading's FULC Position: Q2 2024 in Review

Wolverine Trading sold out of Fulcrum Therapeutics (FULC) in Q2 2024, closing a stake of 23,579 shares — an estimated $179K sold.

Wolverine Trading first reported a position in FULC in Q4 2023 and held it in 2 quarters. The position peaked at $223K in Q1 2024. 121 funds tracked by Wall St. Rank hold FULC as of Q2 2024.

  • Wolverine Trading reported no remaining Fulcrum Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wolverine Trading sold 23,579 Fulcrum Therapeutics shares in Q2 2024, an estimated $179K.
  • Wolverine Trading first reported a position in Fulcrum Therapeutics in Q4 2023 and held it in 2 quarters.
  • Wolverine Trading's Fulcrum Therapeutics position peaked at $223K in Q1 2024.
  • 121 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2024.

Based on Wolverine Trading's 13F filing for Q2 2024, filed 14 Aug 2024.